Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-28T19:09:11.317Z Has data issue: false hasContentIssue false
  • English
  • Français

Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area

Published online by Cambridge University Press:  15 May 2009

M. J. Dwyer  and
P. G. McIntyre
M. J. Dwyer
Affiliation:
Anglia and Oxford Regional Health Authority
P. G. McIntyre*
Affiliation:
Clinical Microbiology and Public Health Laboratory, Cambridge
*
* Dr P. G. McIntyre, Department of Medical Microbiology, Level 6, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The costs and projected benefits of universal screening for hepatitis B virus (HBV) infection in pregnant women in East Anglia are calculated and compared with current practice. By adjusting data from West Midlands region for ethnicity, the prevalence of maternal hepatitis B surface-antigen (HBsAg) positivity in East Anglia is predicted to be 0·083% (1 in 1200). Published data on health risks of perinatal HBV infection and on immunisation efficacy are used to derive benefits of screening. The marginal direct cost of screening is identified from regional sources. Current clinical practice in East Anglia identifies 7 surface-antigen positive mothers per year, whereas 22 are expected. Routine antenatal screening in East Anglia would prevent 2·6 additional childhood carriers per year (compared with current practice), resulting in the prevention of 0·7 deaths per year occuring 40–50 years in the future. The direct cost per (undiscounted) life-year saved would be £2437, not including savings on treatment for chronic hepatitis B infection. Routine prenatal screening for maternal HBsAg should be introduced without delay and continue even if HBV vaccination is introduced into the UK childhood immunisation schedule.

Type
Research Article
Information
Epidemiology & Infection , Volume 117 , Issue 1 , August 1996 , pp. 121 - 131
Copyright
Copyright © Cambridge University Press 1996

References

1.Brown, JL, Thomas, HC.Chronic type B hepatitis. Medicine International 1990; 84: 3465–9.Google Scholar
2.Benenson, AS.Control of communicable diseases in man, 15th ed.Washington: American Public Health Association, 1990; 200–7.Google Scholar
3.UK Health Departments. Immunisation against infectious disease. London: HMSO, 1992; 110–9.Google Scholar
4.Sherlock, S.Hepatitis. B: the disease. Vaccine 1990; 8 (suppl): S6–9.CrossRefGoogle ScholarPubMed
5.Wheeley, SM, Tarlow, MJ, Boxall, EH.Chronic heptatitis B in male and female children of HBsAg carrier mothers. J Hepatology 1989; 8: 226–31.CrossRefGoogle Scholar
6.Boxall, EH, Harrison, TJ, Wheeley, SM.HBV-DNA levels in hepatitis B carrier mothers: relationship with protection against perinatal transmission by vaccine. In: Blaine-Hollinger, F, Lemon, SM, Margolis, HS, eds. Viral hepatitis and liver disease. Houston: Williams & Wilkins, 1990; 757–9.Google Scholar
7.Beasley, RP, Hwang, LY, Lee, GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; ii: 1099–102.CrossRefGoogle Scholar
8.Kane, MA, Hadler, SC, Margolis, HS, Maynard, JE.Routine prenatal screening for hepatitis B surface antigen. JAMA 1988; 259: 408–9.CrossRefGoogle ScholarPubMed
9.Tormans, G, Van Damme, P, Carrin, G, Clara, R, Eylenbosch, W.Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus – the case of Belgium. Soc Sci Med 1993; 37: 173–81.CrossRefGoogle ScholarPubMed
10.Beasley, RP, Hwang, L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas, GN, Dienstag, JL, Hoofnagle, JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 1984; 209–24.Google Scholar
11.Boxall, EH.Antenatal screening for carriers of hepatitis B virus. BMJ 1995; 311: 1178–9.CrossRefGoogle ScholarPubMed
12.Wheeley, SM, Jackson, PT, Boxall, EH, et al. Prevention of perinatal transmission of hepatitis B virus: a comparison of two prophylactic schedules. J Med Virol 1991; 35: 212–5.CrossRefGoogle ScholarPubMed
13.Wheeley, SM, Boxall, EH, Tarlow, MJ, et al. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: Final report on a West Midlands pilot study. J Med Virol 1990; 30: 113–6.CrossRefGoogle Scholar
14.Government Statistical Service. 1991 Census report for England (part I, Vol. 1). London: HMSO; 1993; 92–106.Google Scholar
15.Beasley, RP, Trepo, C, Stevens, CE, Szmuness, W.The eantigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105: 94–8.CrossRefGoogle Scholar
16.Woo, D, Cummins, M, Davies, PA, et al. Vertical transmission of hepatitis B surface antigen in carrier mothers in two West London hospitals. Arch Dis Child 1979; 54: 670–5.CrossRefGoogle ScholarPubMed
17.Polakoff, S, Vandervelde, EM.Immunisation of neonates at high risk of hepatitis B in England and Wales: national surveillance. BMJ 1988; 297: 249–53.Google Scholar
18.Beath, SV, Boxall, Eh, Watson, RM, Tarlow, MJ, Kelley, DA.Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ 1992; 304: 1169–70.CrossRefGoogle ScholarPubMed
19.Sinatra, FR, Shah, P, Weissman, JY, Thomas, DW, Merritt, RJ, Tong, MJ.Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers. Pediatrics 1982; 70: 557–9.Google Scholar
20.Wong, VC, Ip, HM, Reesink, HW, et al. Prevention of the HBsAg carrier state in new-born infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunglobulin. Lancet 1984; i: 921–6.CrossRefGoogle Scholar
21.Stevens, CE, Taylor, PE, Tong, MJ, et al. Yeast-recombinant hepatitis B vaccine. JAMA 1987; 257: 2612–6.Google Scholar
22.Andre, FE.Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 (suppl): S74–8.CrossRefGoogle ScholarPubMed
23.Beasley, RP, Hwang, L-Y, Lin, C-C, Chien, C-S.Hepatocellular carcinoma and hepatitis B virus. Lancet 1981; ii: 1129–33.CrossRefGoogle Scholar
24.Johnson, PJ, Krasner, N, Portmann, B, Eddleston, AL, Williams, R.Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut 1978; 19: 1022–6.Google Scholar
25.Margolis, HS, Coleman, PJ, Brown, RE, Mast, EE, Sheingold, SH, Arevalo, JA.Prevention of hepatitis B virus transmission by immunisation: an economic analysis of current recommendations. JAMA 1995; 274: 1201–8.CrossRefGoogle ScholarPubMed
26.Beasely, RP, Hwang, LY.Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147: 185–90.CrossRefGoogle Scholar
27.Tan, CC, Guan, R, Yap, I, Tay, HH, Kang, JY.Horizontal or vertical transmision of hepatitis B virus? A serological survey in family members of hepatitis B carriers in Singapore. Trans Roy Soc Top Med Hyg 1991; 85: 656–9.CrossRefGoogle ScholarPubMed
28.Yeoh, EK.Hepatitis B virus infection in children. Vaccine 1990; 8 (suppl): S29–S30.CrossRefGoogle ScholarPubMed
29.Department of Health. Health of the nation. London: HMSO, 1992: 12–25.Google Scholar
30.Economics and Operational Research Division. Register of cost-effectiveness studies. Department of Health 1994; (August); F1–F32.Google Scholar
31.Bendixen, HH.The costs of neonatal intensive care. In: Bunker, JP, Barnes, BA, Mosteller, FK, eds. Costs, risks and benefits of surgery. Oxford: Oxford University Press, 1977: 372–84.Google Scholar
32.Buxton, MJ, West, RR.Cost-benefit analysis of long term haemodialysis for chronic renal failure. BMJ 1975; 2: 376–9.CrossRefGoogle ScholarPubMed
33.Casscells, W.Heart transplantation: recent policy developments. NEJM 1986; 315: 1365–8.Google Scholar
34.Kankaanpaa, J.Cost-effective of liver transplantation. Transpl Proc 1987; 19: 3864–6.Google Scholar
35.Klarman, HE, Francis, JO, Rosenthal, JD.Cost effectivenes analysis applied to the treatment of renal disease. Medical Care 1968; 6: 48–54.Google Scholar
36.Spring, DB, Queensbury, CP.Costs of low osmolar contrast media. JAMA 1991; 1081–2.CrossRefGoogle ScholarPubMed
37.Weinstein, MC, Stason, WB.Cost effectiveness of coronary artery bypass grafting. Circulation 1982; 66 (suppl 3): 56–66.Google Scholar
38.Discounting health care: only a matter of timing? Lancet 1992; 340: 148–9.CrossRefGoogle Scholar
39.Parsonage, M, Neuburger, H.Discounting and health benefits. Hlth Econ 1992; 1: 71–6.Google Scholar
40.Sheldon, TA.Discounting in health care decision making: time for a change? J Public Hlth Med 1992; 14: 250–6.Google Scholar
41.Arevalo, JA, Washington, AE.Cost-effectiveness of prenatal screening and immunisation for hepatitis B virus. JAMA 1988; 259: 365–9. [correction in JAMA 1988; 260: 478].CrossRefGoogle ScholarPubMed
42.Kane, MA, Hadler, SC, Margolis, HS, Maynard, JE.Routine prenatal screening for hepatitis B surface antigen. JAMA 1988; 259: 408–9.CrossRefGoogle ScholarPubMed
43.Smith, CP, Parle, M, Morris, DJ.Implementation of government recommendations for immunising infants at high risk of hepatitis. B. BMJ 1994; 309: 1339.CrossRefGoogle Scholar
44.Alter, MJ.Community acquire viral hepatitis B and C in the United States. Gut 1993; 2 (suppl): S17–19.Google Scholar
45.McQuillan, GM, Townsend, TR, Johannes, CB, Dillard, T, Molteni, RA, Ness, PM.Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity and predictive value of the recommended screening questions to detect high-risk women in an obstetrc population. Am J Epidemiol 1987; 126: 484–91.Google Scholar
46.PHLS Hepatitis Subcommittee. Exposure to hepatitis B virus: guidance on post-exposure prophylaxis. CDR 1992 2: R97–101.Google Scholar
47.Chrystie, I, Sumner, D, Palmer, S, Kenney, A, Banatvala, J.Screening of pregnant women for evidence of current hepatitis B infection: selective or universal? Hlth Trends 1992; 24: 13–5.Google Scholar
48.Mangtani, P, Hall, AJ, Normand, CEM.Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Commun Hlth 1995; 49: 238–44.CrossRefGoogle ScholarPubMed
49.Kane, MA.Progress on the control of hepatitis B infection through immunisation. Gut 1993; 2 (suppl): S10–2.Google Scholar
50.Dobson, S, Scheifele, D, Bell, A.Assessment of a universal school based hepatitis B vaccination program. JAMA 1995; 274: 1209–13.Google Scholar
51.Francis, DP.The public's health unprotected: reversing a decade of underutilization of hepatitis B vaccine. JAMA 1995; 274: 1242–3.Google Scholar
52.Committee on Health Promotion, Faculty of Public Health Medicine. Hepatitis B. Guidelines for health promotion 1993: 35.Google Scholar